S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
S&P 500   5,251.81 (+0.06%)
DOW   39,741.24 (-0.05%)
QQQ   444.33 (-0.11%)
AAPL   170.81 (-1.44%)
MSFT   420.69 (-0.18%)
META   489.70 (-0.84%)
GOOGL   150.41 (-0.30%)
AMZN   180.82 (+0.55%)
TSLA   176.92 (-1.62%)
NVDA   905.92 (+0.38%)
NIO   4.62 (-1.07%)
AMD   182.99 (+1.89%)
BABA   72.32 (+1.02%)
T   17.55 (+0.00%)
F   13.21 (+1.15%)
MU   118.42 (-0.60%)
CGC   9.11 (-4.61%)
GE   176.00 (-2.29%)
DIS   122.34 (+1.12%)
AMC   3.75 (-13.59%)
PFE   27.84 (+0.22%)
PYPL   66.94 (+0.56%)
XOM   115.38 (+0.36%)
NASDAQ:MLTX

MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis

$49.06
-1.15 (-2.29%)
(As of 10:34 AM ET)
Today's Range
$48.70
$50.93
50-Day Range
$43.78
$63.86
52-Week Range
$17.82
$64.98
Volume
56,231 shs
Average Volume
468,603 shs
Market Capitalization
$3.13 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$73.42

MoonLake Immunotherapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.82 Rating Score
Upside/​Downside
46.2% Upside
$73.42 Price Target
Short Interest
Bearish
14.83% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.83mentions of MoonLake Immunotherapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$9.49 M Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.11) to ($1.56) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

564th out of 939 stocks

Pharmaceutical Preparations Industry

263rd out of 433 stocks

MLTX stock logo

About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

MLTX Stock Price History

MLTX Stock News Headlines

MLTX Aug 2024 80.000 call
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
MLTX May 2024 60.000 call
MLTX Apr 2024 40.000 put
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
MoonLake Stock (NASDAQ:MLTX), Short Interest Report
MLTX Mar 2024 80.000 call
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics Class A
See More Headlines
Receive MLTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/29/2024
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MLTX
Fax
N/A
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$73.42
High Stock Price Target
$92.00
Low Stock Price Target
$56.00
Potential Upside/Downside
+49.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.82
Research Coverage
11 Analysts

Profitability

Net Income
$-36,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.15 per share

Miscellaneous

Free Float
54,131,000
Market Cap
$3.13 billion
Optionable
Optionable
Beta
1.20
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

MLTX Stock Analysis - Frequently Asked Questions

Should I buy or sell MoonLake Immunotherapeutics stock right now?

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MoonLake Immunotherapeutics in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MLTX shares.
View MLTX analyst ratings
or view top-rated stocks.

What is MoonLake Immunotherapeutics' stock price target for 2024?

11 Wall Street analysts have issued 1 year target prices for MoonLake Immunotherapeutics' shares. Their MLTX share price targets range from $56.00 to $92.00. On average, they expect the company's stock price to reach $73.42 in the next twelve months. This suggests a possible upside of 46.2% from the stock's current price.
View analysts price targets for MLTX
or view top-rated stocks among Wall Street analysts.

How have MLTX shares performed in 2024?

MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of 2024. Since then, MLTX shares have decreased by 16.9% and is now trading at $50.21.
View the best growth stocks for 2024 here
.

When is MoonLake Immunotherapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our MLTX earnings forecast
.

How were MoonLake Immunotherapeutics' earnings last quarter?

MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its quarterly earnings data on Thursday, February, 29th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.11.

Who are MoonLake Immunotherapeutics' major shareholders?

MoonLake Immunotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avoro Capital Advisors LLC (4.13%), Price T Rowe Associates Inc. MD (3.71%), Price T Rowe Associates Inc. MD (3.71%), Federated Hermes Inc. (1.70%), Finepoint Capital LP (1.43%) and Westfield Capital Management Co. LP (0.98%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Kristian Reich and Matthias Bodenstedt.
View institutional ownership trends
.

How do I buy shares of MoonLake Immunotherapeutics?

Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MLTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners